Skip to main content
. Author manuscript; available in PMC: 2019 May 21.
Published in final edited form as: Hepatology. 2015 Mar 25;62(2):546–557. doi: 10.1002/hep.27764

Figure 3. Depletion of hepatic MDSCs prior to initial halothane treatment resulted in increased serum levels of immunoglobulins against hepatic TFAPA.

Figure 3

(A) Serum immunoglobulin against TFA-protein adducts was measured by coating microplates with microsomal extracts from livers of either halothane or oil-treated mice. Antibodies were detected at 1:400 dilution of serum and the results were corrected by subtracting the OD value of wells coated with microsomal proteins from oil-treated mice. Data reported as mean ± SEM of 8-15 mice per group obtained from 3 independent experiments. (B) Serum protein concentrations of IL-4 were measured in isotype or anti-Gr-1 treated mice 9 days after halothane rechallenge with N=5-12 per group from 2 independent experiments. *P<0.05 versus isotype-treated group. (C) Analysis of TFAPA-specific immunoglobulin (Ig) subclasses in serum 9 days post halothane rechallenge. Antibodies were detected at 1:100 dilution of serum and results were corrected by subtracting the OD value of wells coated with microsomal proteins from oil-treated mice. N=4-9 per group from 2 independent experiments. *P<0.05 versus isotype-treated group within the same Ig subclass. All data reported as means ± SEM.